The queries since the May victory are worth around $ 1.5 billion, according to a back of the envelope calculation.

Sun Pharma will be in a better position to manage Ranbaxy. They have handled overseas acquisitions successfully, says Ajay Piramal.

Ranbaxy pared most of its morning gains and was trading 1.6 per cent lower at Rs 452.05. It hit a low of Rs 445 and a high of Rs 505 in tra...

The Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.

The deal values Ranbaxy shares at Rs 457 apiece, representing an 18 per cent premium to their 30-day volume-weighted average share price.

"It is difficult to predict the outcome of the dispute between Daiichi Sankyo and the Singh brothers, the company has already witnessed the...

Unlike many of its global peers, the $35.8 billion private equity giant Apax Partners, has been relatively quiet in India making only 2 tra...

Ranbaxy Laboratories' net profit grew more than two-and-a-half times in its third quarter ended September 30, 2010. The initial euphoria to...

The promoters of Super Religare Laboratories Malvinder and Shivinder Singh may buyout Piramal Heathcare’s 10% stake in the country’s larges...

Larsen & Toubro is learnt to have appointed Japanese financial services firm Nomura to advise it on a possible deal with Satyam.

Larsen & Toubro is learnt to have appointed Japanese financial services firm Nomura to advise it on a possible deal with Satyam.

FDI inflows declined 26% in October this year compared to the same month last year, commerce minister Kamal Nath told the Lok Sabha on Tues...

Overseas firms may not require the government’s approval to acquire stake in local companies through warrants, according to a senior indust...

The Japanese company planned to run a full-fledged operations in India and had long-terms plans for India.